All In Biotech

Drug Trial Radar · NCT05891366

Single Ascending Dose Study of WAL0921 in Healthy Subjects

Safety, Pharmacokinetics, and Pharmacodynamics of a Single, Ascending Dose of WAL0921 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Apr 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

May 31, 2023

Primary completion

Jan 9, 2024

Study completion Jan 9, 2024

Sponsor

Lead sponsor
Walden BiosciencesIndustry
Sponsor type
Industry
First posted
Jun 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, pharmacokinetics, and pharmacodynamics of WAL0921 in healthy subjects.

Conditions

  • Healthy

Interventions

  • WAL0921Drug

    Investigational product WAL0921

  • PlaceboDrug

    Placebo product

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment emergent adverse eventsTime frame: Day 1 to Day 64

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PPD Pharmacology Unit

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.